Meiji Yasuda America Inc Makes New $3.59 Million Investment in Stryker Corporation $SYK

Posted by Geri Gentry on Jun 12th, 2026

Meiji Yasuda America Inc bought a new position in shares of Stryker Corporation (NYSE:SYK – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 10,215 shares of the medical technology company’s stock, valued at approximately $3,590,000.

Other large investors have also recently added to or reduced their stakes in the company. United Financial Planning Group LLC acquired a new position in shares of Stryker during the 3rd quarter worth about $27,000. Godfrey Financial Associates Inc. acquired a new position in shares of Stryker during the 4th quarter worth about $26,000. Strive Asset Management LLC acquired a new position in shares of Stryker during the 3rd quarter worth about $30,000. CGC Financial Services LLC acquired a new position in shares of Stryker during the 4th quarter worth about $29,000. Finally, ANTIPODES PARTNERS Ltd acquired a new position in shares of Stryker during the 3rd quarter worth about $34,000. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently commented on SYK. BTIG Research reduced their price objective on shares of Stryker from $397.00 to $379.00 and set a “buy” rating for the company in a research note on Friday, May 1st. JPMorgan Chase & Co. reduced their price objective on shares of Stryker from $445.00 to $400.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Needham & Company LLC reduced their price objective on shares of Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Wells Fargo & Company reduced their price objective on shares of Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a $465.00 price objective on shares of Stryker in a research note on Wednesday, March 4th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

View Our Latest Stock Analysis on Stryker

Stryker Trading Down 1.0%

Shares of NYSE:SYK opened at $305.82 on Friday. Stryker Corporation has a 52-week low of $281.00 and a 52-week high of $404.87. The company has a market capitalization of $117.24 billion, a P/E ratio of 35.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The company has a 50-day simple moving average of $316.75 and a 200 day simple moving average of $344.20. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.25 and a current ratio of 2.11.

Stryker (NYSE:SYK – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical technology company reported $2.60 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analyst estimates of $6.34 billion. During the same quarter last year, the business posted $2.84 earnings per share. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio (DPR) is 40.74%.

Insider Activity at Stryker

In other Stryker news, VP M Kathryn Fink sold 3,500 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $283.45, for a total value of $992,075.00. Following the transaction, the vice president directly owned 177 shares of the company’s stock, valued at $50,170.65. This represents a 95.19% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the completion of the transaction, the vice president directly owned 10,582 shares in the company, valued at approximately $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.